Developability and Immunosafety: Don’t let them threaten your drug development plans

Advancing your drug candidate from late-stage discovery into the clinic is one of the most critical steps in development. To maximize your chances of success, it is essential to de-risk your candidate(s) as soon as possible. While manufacturability and immunosafety issues can threaten your molecule’s path to the clinic, they can be predicted and managed very early in the development journey based on the candidate’ sequence and structure.

Join our expert Dr. Yvette Stallwood, Head of Early Development Services at Lonza Biologics to explore the challenges and key considerations to de-risk your biotherapeutic(s). Learn how in silico and in vitro design and optimization tools allow you to assess and mitigate risks early and ultimately increase the likelihood of a successful First-in-Human campaign.

Participants will learn about

• Explore the challenges, key considerations and pitfalls of designing and performing developability and immunogenicity assessments.
• Learn about how this knowledge allows for modifications to the drug candidate to mitigate risk early and increase the likelihood of a successful first-in-human study.

Who should Attend